



## Population Immunity and Persistence to SARS-CoV-2 Induced by Infection and Vaccination, Protection against New Infections and Implication for Further Vaccination

Guest Editor:

**Dr. Juan Yang**

School of Public Health, Fudan  
University, Shanghai, China

Deadline for manuscript  
submissions:

**31 October 2024**

### Message from the Guest Editor

Dear Colleagues,

Although the World Health Organization declared the end to COVID-19's emergency phase, SARS-CoV-2 will be around for a long time and the risk of new variants remains. Having a good knowledge of the population immunity landscape and dynamics and understanding its protection against infections of variants and the severity after infections are critical for policymaking on actions that countries should take in the new phase of the COVID-19 pandemic. The Special Issue aims to collect the latest research results on the sero-epidemiological characteristics of SARS-CoV-2 infections and vaccination. With this in mind, we are pleased to invite the submission of original research articles and reviews investigating the infection incidence and its severity, population immunity landscape, the kinetics of antibodies following prior infections (with any variant), vaccination (particularly post-licensure), or both (hybrid immunity), protection (and cross-protection) against new variants infections, and providing new ideas for the COVID-19 vaccination strategy in the future.

Dr. Juan Yang  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)